Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
| ▸ | TUBB | P07437 | 2/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193222 | 0.93 | CRHR1 (0.49) | CRHR1EGFRPDGFRBKDRTUBB4A | |
| SCHEMBL5493194 | 0.79 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL5493196 | 0.79 | CRHR1 (0.44) | CRHR1CNR1 | |
| SCHEMBL5496770 | 0.79 | CRHR1 (0.42) | CRHR1DRD2CNR1 | |
| SCHEMBL5494959 | 0.79 | CRHR1 (0.47) | CRHR1OPRM1ROCK1CNR1 | |
| SCHEMBL5039336 | 0.78 | CRHR1 (0.42) | CRHR1OPRM1CACNA2D1CACNA2D2CNR1 | |
| SCHEMBL5492348 | 0.77 | CRHR1 (0.43) | CRHR1CNR1 | |
| SCHEMBL5493199 | 0.77 | CRHR1 (0.45) | CRHR1DRD2CNR1 | |
| SCHEMBL5493174 | 0.77 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL5492343 | 0.77 | CRHR1 (0.52) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | CRHR1 1/4885EGFR 1052/4885PDGFRB 2973/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CRHR1 2/4885EGFR 2026/4885PDGFRB 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.